Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Has the Pediatric Asthma Treatment Market Performed Historically, and What Are Its Future Growth Projections?
The pediatric asthma treatment market size has grown strongly in recent years. It will grow from $11.03 billion in 2024 to $11.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising incidence of childhood asthma, growing awareness about respiratory disorders in children, an increase in air pollution and environmental allergens, rising healthcare expenditure on pediatric care, and campaigns by NGOs and healthcare organizations on asthma awareness.
The pediatric asthma treatment market size is expected to see strong growth in the next few years. It will grow to $14.39 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing prevalence of allergic disorders in children, expansion of biologic therapies for severe pediatric asthma, rising investments in pediatric drug development, growing emphasis on personalized and precision medicine, and rising middle-class population with access to private care. Major trends in the forecast period include developing pediatric-friendly biologic therapies, developing rapid allergen identification tools, integration of electronic health records, innovation in inhaler formulations, and innovation in immunotherapy for asthma.
Get your free report sample today:
What Are the Essential Drivers Propelling the Pediatric Asthma Treatment Market Forward?
The increasing prevalence of respiratory infections is expected to propel the growth of the pediatric asthma treatment market going forward. Respiratory infections refer to illnesses caused by viruses, bacteria, or other pathogens that affect the respiratory tract, including the nose, throat, airways, and lungs. The rising prevalence of respiratory infections is primarily due to rising air pollution, as exposure to pollutants such as particulate matter and nitrogen dioxide weakens the respiratory system and makes individuals more susceptible to infections. Pediatric asthma treatment helps reduce the frequency and severity of respiratory infections by improving airway function and minimizing inflammation, which lowers vulnerability to infectious triggers. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, chronic obstructive pulmonary disease contributed to 3.6% of the total disease burden and accounted for 50% of the total burden of respiratory conditions. Additionally, in 2022, an estimated 638,000 people (2.5% of the population) in Australia were living with chronic obstructive pulmonary disease. Therefore, the increasing prevalence of respiratory infections drives the growth of the pediatric asthma treatment market.
What Are the Primary Market Segments in the Pediatric Asthma Treatment Market?
The pediatric asthma treatment market covered in this report is segmented –
1) By Type: Long-Term Control Medications, Quick-Relief Medications, Other Types
2) By Drug Class: Inhaled Corticosteroids, Long-Acting Beta Agonists, Leukotriene Modifiers, Antihistamines, Biologics
3) By Route Of Administration: Oral Route, Nasal Route, Injectable Route
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Clinics, Home Care, Other End users
Subsegments:
1) By Long-Term Control Medications: Inhaled Corticosteroids, Leukotriene Modifiers, Long-Acting Beta Agonists, Combination Inhalers, Biologic Therapies
2) By Quick-Relief Medications: Short-Acting Beta Agonists, Anticholinergics, Systemic Corticosteroids
3) By Other Types: Immunotherapy, Methylxanthines, Alternative Therapies
What New Market Trends Are Emerging in the Pediatric Asthma Treatment Market?
Major companies operating in the pediatric asthma treatment market, focusing on developing innovative therapies, such as monoclonal antibodies, to target and reduce airway inflammation in children. Monoclonal antibodies are laboratory-made proteins designed to mimic the immune system's ability to fight off harmful pathogens by specifically targeting certain cells or substances. For instance, in April 2024, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration for FASENRA (benralizumab) as an add-on maintenance treatment for children aged 6 to 11 years with severe asthma characterized by an eosinophilic phenotype. This antibody is designed to reduce asthma exacerbations and improve symptom control by targeting and eliminating eosinophils. Fasenra is administered via subcutaneous injection once every 4 weeks for the first three doses, followed by once every 8 weeks, with pediatric dosing adjusted based on body weight.
Who Are the Top Performers and Innovators in the Pediatric Asthma Treatment Market?
Major companies operating in the pediatric asthma treatment market are Pfizer Inc., Merck And Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Lupin Limited, Zydus Lifesciences Ltd., ECU Health.
Get the detailed pediatric asthma treatment market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the pediatric asthma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric asthma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment